A Score-Based Approach to18F-FDG PET Images as a Tool to Describe Metabolic Predictors of Myocardial Doxorubicin Susceptibility by Bauckneht, Matteo et al.
diagnostics
Article
A Score-Based Approach to 18F-FDG PET Images as
a Tool to Describe Metabolic Predictors of Myocardial
Doxorubicin Susceptibility
Matteo Bauckneht 1,* ID , Silvia Morbelli 1, Francesco Fiz 1,2, Giulia Ferrarazzo 1, Roberta Piva 1,
Alberto Nieri 1, Matteo Sarocchi 3, Paolo Spallarossa 3, Maria Elisa Canepari 4,
Eleonora Arboscello 5, Andrea Bellodi 5, Massimo Massaia 4, Andrea Gallamini 6, Paolo Bruzzi 7,
Cecilia Marini 8 and Gianmario Sambuceti 1
1 Nuclear Medicine, Policlinico San Martino Hospital and Department of Health Sciences,
University of Genoa, 16132 Genoa, Italy; silviadaniela.morbelli@hsanmartino.it (S.M.);
francesco.fiz.nm@gmail.com (F.F.); giulia.ferrarazzo@gmail.com (G.F.); pivaroberta@hotmail.it (R.P.);
albertonieri@yahoo.it (A.N.); sambuceti@unige.it (G.S.)
2 Nuclear Medicine Unit, Department of Radiology, Uni-Klinikum, 72070 Tübingen, Germany
3 Clinic of Cardiovascular Diseases, Policlinico San Martino Hospital, 16132 Genoa, Italy;
sarocchi@gmail.it (M.S.); spallarossa@unige.it (P.S.)
4 Ematology Unit, ASO Santa Croce e Carle, 12100 Cuneo, Italy; me.canepari@libero.it (M.E.C.);
massimo.massaia@unito.it (M.M.)
5 Clinic of Internal Medicine 3, Department Internal Medicine, Policlinico San Martino Hospital,
16132 Genoa, Italy; eleonora.arboscello@hsanmartino.it (E.A.); andreabellodi@libero.it (A.B.)
6 Department of Research, Innovation and Statistics, Antoine Lacassagne Cancer Centre, 06189 Nice, France;
andreagallamini@gmail.com
7 Epidemiology Unit, Policlinic San Martino Hospital, 16132 Genoa, Italy; paolo.bruzzi@hsanmartino.it
8 CNR Institute of Bioimaging and Molecular Physiology, Section of Genoa, 20090 Milan, Italy;
cecilia.marini@unige.it
* Correspondence: matteo.bauckneht@gmail.com; Tel.: +39-010-555-4810; Fax: +39-010-555-6911
Received: 12 September 2017; Accepted: 23 October 2017; Published: 26 October 2017
Abstract: Purpose: To verify the capability of 18F-fluorodeoxy-glucose positron emission
tomography/computed tomography (FDG-PET/CT) to identify patients at higher risk of developing
doxorubicin (DXR)-induced cardiotoxicity, using a score-based image approach. Methods:
36 patients underwent FDG-PET/CT. These patients had shown full remission after DXR-based
chemotherapy for Hodgkin’s disease (DXR dose: 40–50 mg/m2 per cycle), and were retrospectively
enrolled. Inclusion criteria implied the presence of both pre- and post-chemotherapy clinical
evaluation encompassing electrocardiogram (ECG) and echocardiography. Myocardial metabolism at
pre-therapy PET was evaluated according to both standardized uptake value (SUV)- and score-based
approaches. The capability of the score-based image assessment to predict the occurrence of cardiac
toxicity with respect to SUV measurement was then evaluated. Results: In contrast to the SUV-based
approach, the five-point scale method does not linearly stratify the risk of the subsequent development
of cardiotoxicity. However, converting the five-points scale to a dichotomic evaluation (low vs. high
myocardial metabolism), FDG-PET/CT showed high diagnostic accuracy in the prediction of cardiac
toxicity (specificity = 100% and sensitivity = 83.3%). In patients showing high myocardial uptake
at baseline, in which the score-based method is not able to definitively exclude the occurrence of
cardiac toxicity, myocardial SUV mean quantification is able to further stratify the risk between
low and intermediate risk classes. Conclusions: the score-based approach to FDG-PET/CT images
is a feasible method for predicting DXR-induced cardiotoxicity. This method might improve the
inter-reader and inter-scanner variability, thus allowing the evaluation of FDG-PET/CT images in
a multicentral setting.
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1. Introduction
The use of systemic chemotherapy is the main form of treatment in case of hematological
malignancies. While allowing a curative effect, its greatest drawback resides in the need to find
a balance between therapeutic effectiveness and the onset of future complications, especially in the
setting of younger patients. In fact, starting 30 years after treatment, the cumulative mortality from
therapy-related medical illness actually exceeds that from cancer recurrence [1]. This phenomenon
is attributable to both secondary malignancies and late cardiotoxicity [2–4] and can considerably
impair life expectancy in younger patients. Moreover, the occurrence of cardiac injury can decisively
affect both overall performance status as well as quality of life, particularly in elderly subjects,
in patients with cardiovascular comorbidities, or in those in which additional thoracic irradiation is
indicated [4–7]. In these regards, dose-dependent anthracycline-induced cardiomyopathy is one of the
most acknowledged and well-studied clinical models of cardiovascular toxicity by chemotherapy.
The pathogenic mechanisms of late-onset anthracyclines-related myocardial damage has been
to this day not fully explained. Several studies pointed out that doxorubicin (DXR), one of the most
utilized anthracyclines, can specifically affect myocardial metabolic processes. Evaluation of in vivo
glucose metabolism by means of molecular imaging confirmed this hypothesis, highlighting altered
glucose uptake pattern, both in experimental animals and humans [8–11]. Accordingly, an in vitro
study highlighted mitochondrial dysfunction in cardiomyocites exposed to DXR; this finding was
associated with increased glucose consumption, possibly due to enhanced anaerobic glycolysis [12].
This pattern may be detected by 18F-fluorodeoxy-glucose positron emission tomography/
computed tomography (FDG-PET/CT): increasing glucose consumption might in fact signal ongoing
mitochondrial failure and a subsequent increase of the less energy-efficient glycolysis [12–14].
Similarly, low FDG-uptake at baseline might indicate a stricter dependence on mitochondrial-based
ATP-generating processes and, thus, a greater susceptibility to DXR-linked damage [8].
For these reasons, the evaluation of FDG-PET/CT in patients treated with a DXR-based regimen
might offer a viable window on metabolic changes within the myocardium, possibly identifying
ongoing myocardial damage.
However, a major limitation is that glucose metabolism activity is evaluated by means of
a standardized uptake value (SUV)-based approach, which might be influenced by several factors
not related to tissue characteristics, including plasma glucose concentration, length of uptake period,
partial volume effects, and recovery coefficient, as well as FDG-PET/CT scanner sensitivity [15].
The error margin due to these factors can actually exceed 50% [15].
This issue has been tackled in clinical nuclear medicine through the introduction of scales able to
standardize metabolic qualitative estimation. An emblematic example is the five-point scale criteria
(also called Deauville criteria), initially proposed for the evaluation of FDG-PET/CT of patients affected
by Hodgkin’s disease (HD) [16]. This approach is based on the visual comparison of relative metabolic
activity in the evaluated tissue with a reference area (mediastinal blood pool and liver) and showed
an excellent inter-observer reproducibility [16]. Following success in HD, the five-point scale has been
tentatively proposed for other malignancies, including non-Hodgkin’s lymphoma [17] and head and
neck cancer [18], as well as for inflammatory diseases such as vasculitis [19,20].
Based on these considerations, the present study aimed: (1) to identify the capability of baseline
FDG to identify patients at higher risk of developing DXR-induced cardiotoxicity using a five-point
scale approach; and (2) to evaluate whether a score-based image evaluation is superior in predicting
myocardial dysfunction with respect to the SUV-based approach in a retrospectively enrolled HD
patient population, submitted to serial FDG-PET/CT before, during, and after DXR administration.
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To achieve this aim, the long-term correlation between the SUV- and score-based analysis of glucose
analogue uptake and longitudinal myocardial function assessed by means of a follow-up clinical
evaluation, ECG and transthoracic echocardiography were evaluated.
2. Materials and Methods
2.1. Patient Enrollment
The present study is a retrospective re-evaluation of FDG-PET/CT scans from a previously
enrolled patient population [8]. The report of that study includes a through description of the materials
and method. Briefly, the study population included HD patients evaluated by means of FDG-PET/CT
performed in our institution from January 2008 to December 2015 according to the following
population inclusion criteria: (1) no history of cardiovascular disease; (2) no diabetes; (3) availability of
a clinical pre- and post-chemotherapy clinical evaluation encompassing electrocardiogram (ECG) and
transthoracic echocardiography; (4) normal findings at pre-therapy clinical evaluation; (5) planned
chemotherapy scheme (Adriamycin, Bleomycin, Vinblastine and Dacarbazine -ABVD-; DXR dose:
40–50 mg/m2 per cycle); (6) available staging FDG-PET/CT scan (PET1); (7) negative interim,
post-therapy and 6 month follow up PET scan according to the Deauville criteria [17]; and (8) no
subsequent HD relapse at late clinical follow-up. This selection process narrowed a final population of
36 patients.
2.2. FDG-PET/CT Scans
In accordance to our standard clinical PET protocol, FDG-PET/CT scans were performed using
a 16-slice Biograph 16 PET/CT hybrid system (Siemens Medical Solutions). After a 6-h fasting state,
each patient received an intravenous bolus of FDG (4.8–5.2 MBq/kg of body weight). PET/CT
acquisition started 60–75 min afterward; in the meantime, the patients were hydrated and encouraged
to urinate, so as to decrease the unbound tracer fraction. The entire body was scanned from vertex
to mid-thigh in arms-up position. The emission scan lasted 120 s per bed position. PET raw data
were reconstructed using ordered-subset expectation maximization (3 iterations and 16 subsets),
and attenuation was corrected using the raw CT data. Then, a 16-detector-row helical CT was
performed with non-diagnostic current and voltage settings (120 kV and 80 mA), a gantry rotation
speed of 0.5 s, and a table speed of 24 mm per gantry rotation. No contrast medium was injected.
The entire CT dataset was fused with the 3-dimensional PET images using an integrated software
interface (Syngo; Siemens Healthcare Headquarters, Erlangen, Germany).
2.3. Image Analysis
Patients’ data were anonymized before executing the retrospective analysis. Only PET1 images
were evaluated. The SUV-based image analysis was performed as detailed elsewhere [8]. Briefly,
an experienced nuclear medicine physician, unaware of cardiotoxic patient’s profile, manually drew
a volume of interest (VOI) on the metabolically active left ventricular myocardium to estimate
SUVmean and SUVmax (termed LV-SUVmean and LV-SUVmax, respectively). Subsequently,
the same images were visually evaluated focusing on myocardium, following five-point scale
criteria [16]. In case of heterogeneous myocardial FDG uptake, the highest uptake was scored and
compared to reference tissues. In patients showing mediastinum or liver disease, only healthy tissue
uptake was considered as reference. Examples of corresponding PET images to different score classes
are shown in Figure 1.
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Figure 1. Score-based approach to 18F-fluorodeoxy-glucose positron emission tomography/computed 
tomography (FDG-PET/CT) images. Examples of score-based evaluation of myocardial FDG uptake 
among the 36 enrolled Hodgkin’s disease (HD) patients. None of PET1 myocardial images was 
classified as score 1. 
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syncope, chest pain or dyspnea), physical examination, and baseline ECG. A transthoracic 
echocardiogram was also performed to estimate wall thickness, left ventricular (LV) diameters and 
ejection fraction (EF) calculated with Simpson method [21]. LV diastolic function was assessed by the 
E/A wave ratio and by E wave deceleration time [21]. 
2.5. Statistical Analysis 
All data are presented as mean ± standard deviation (SD). Differences between paired and 
unpaired data were analyzed through Student t-test and the chi-squared test for categorical variables. 
The capability of the score-based image investigation to predict cardiotoxicity was tested by means 
of a univariate analysis. 
Furthermore, receiver-operating characteristic (ROC) curve analysis was performed to evaluate 
the capability of both five-point scale and LV-SUV to discriminate between individuals who 
developed or not cardiac toxicity and to determine the corresponding cut-off values. As post hoc 
analysis, this value was tested to identify the best predictor of cardiotoxicity. A probability value p < 
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or not cardiac toxicity and to determine the corresponding cut-off values. As post hoc analysis,
this value was tested to identify the best predictor of cardiotoxicity. A probability value p < 0.05
was considered statistically significant. A biomedical statistician performed the statistical analyses
using a dedicated software application (SPSS, IBM Corp. Released 2012, Version 21.0. IBM Corp.:
Armonk, NY, USA).
3. Results
3.1. Clinical Data and Myocardial Functional Outcome
Demographic and clinical data of patient population are detailed elsewhere [8]. Median follow-up
time between the end of chemotherapy and clinical re-evaluation was 27 months (range: 8–96 months).
None of the 36 enrolled patients reported any hospitalization potentially related to cardiac disorders.
According to the inclusion criteria, pre-therapy LV dimensions and function were remarkably similar
in all patients. However, in the later clinical follow-up, ECG or echocardiography documented new
onset abnormalities in 11/36 patients (30%, 4 females, mean age 44± 17, age range 21–66). Appearance
of cardiac abnormality was not related to differences in age, gender, body weight, gycaemia at tracer
injection and cardiovascular risk profile (including hypertension, tobacco use, total cholesterol, LDL,
triglycerides, creatinine and family history of coronary artery disease), mediastinal radiotherapy,
total DXR dose, or follow-up duration [8]. According to the population inclusion criteria none of the
36 patients was affected by diabetes.
3.2. Score-Based vs. SUV-Based Image Analysis
As previously showed, a baseline SUV-based image analysis is able to predict DXR-induced
cardiac toxicity. Results of SUV-based analysis of images are detailed elsewhere [8]. Briefly,
the 11 “cardiotoxic” patients displayed markedly lower myocardial SUV mean values at baseline with
respect to the remaining 25.
Details about the relationship between the occurrence of DXR-related cardiac toxicity and
score-based images evaluation are summarized in Table 1. The five-point scale does not linearly
stratify the risk of the subsequent development of cardiac toxicity. Based on this finding, a post hoc
analysis was conducted, converting the 5-point scale to a dichotomic evaluation. A score of <3 was
classified as “low myocardial uptake”, while a score ≥3 was termed as “high myocardial uptake”.
This latter approach showed a high accuracy (specificity = 100% and sensitivity = 83.3%, Table 2).
Subsequently, the cut-off SUV-based and dichotomist score-based approaches were compared
(Table 3). In patients showing a baseline high myocardial uptake, the LV-SUVmean is able to
further stratify the risk between low (LV-SUVmean > 2.015) and intermediate (LV-SUVmean < 2.015)
risk classes.
Table 1. Relationship between DXR-related damage and score-based images evaluation.
Myocardial Damage
Total
0 1.0
Score 2–5
2
Count 0 6 6
% in Score 2–5 0.0% 100.0% 100.0%
3
Count 9 1 10
% in Score 2–5 90.0% 10.0% 100.0%
4
Count 5 3 8
% in Score 2–5 62.5% 37.5% 100.0%
5
Count 11 1 12
% in Score 2–5 91.7% 8.3% 100.0%
Total
Count 25 11 36
% in Score 2–5 69.4% 30.6% 100.0%
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Table 2. Relationship between DXR-related damage and binary images evaluation.
Myocardial Damage
Total
0 1.0
ScoreBin
score: <3
Count 0 6 6
% in ScoreBin 0.0% 100.0% 100.0%
Score: ≥3 Count 25 5 30% in ScoreBin 83.3% 16.7% 100.0%
Total
Count 25 11 36
% in ScoreBin 69.4% 30.6% 100.0%
Table 3. Comparison between cut-off SUV-based and dichotomist score-based evaluation.
Score Myocardial Damage Total
0 1
Score < 3
Binary SUV
myocardium
<2
Count 6 6
% in binary SUV
myocardium 100.0% 100.0%
Total
Count 6 6
% in binary SUV
myocardium 100.0% 100.0%
Score≥ 3
Binary SUV
myocardium
Normal
Count 14 0 14
% in binary SUV
myocardium 100.0% 0.0% 100.0%
<2
Count 11 5 16
% in binary SUV
myocardium 68.8% 31.3% 100.0%
Total
Count 25 5 30
% in binary SUV
myocardium 83.3% 16.7% 100.0%
Total
Binary SUV
myocardium
Normal
Count 14 0 14
% in binary SUV
myocardium 100.0% 0.0% 100.0%
<2
Count 11 11 22
% in binary SUV
myocardium 50.0% 50.0% 100.0%
Total
Count 25 11 36
% in binary SUV
myocardium 69.4% 30.6% 100.0%
4. Discussion
In keeping with our previous findings [8], showing that low myocardial FDG uptake is able to
early identify patients at higher risk of developing DXR-induced cardiac toxicity, in the present study
we demonstrated that not only the SUV-based but also a score-based approach to FDG-PET/CT images
can be proposed in the clinical setting. Accordingly, both these indicators showed a good capability to
predict the subsequent development of cardiac toxicity. However, the score-based evaluation of images
allowed the same accuracy with easier standardization. This approach might, therefore, improve the
inter-reader and inter-scanner variability, thus allowing the evaluation of FDG-PET/CT images as
a tool to predict DXR cardiotoxicity in a multicentric setting.
SUV is the most largely used indicator of glucose analogue avidity in PET cancer studies.
This value is defined as the tissue concentration of tracer as measured by a PET scanner divided
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by the ratio between injected activity and body weight [22]. This index accounts for both the
time elapsed from tracer injection and corrects for the distribution. However, numerous patient-
and equipment-linked factors cause significant discrepancies between scans [15]. Consequently,
the cut-off value obtained by our analysis might not be valid in independent patient populations.
On the other hand, SUV did not add any added predictive value compared with visual inspection in
the clinical setting [23,24]. Differently from SUV-based image analysis, the score-based approach is
less affected by confounding variables known to impact on SUV measurement. Accordingly, the score
is chosen by means of a qualitative interpretation on focal uptake in relation to uptake in adjacent
tissues, which are influenced by technical factors by the same degree, with respect to the target tissue.
Therefore, this method is able to reduce inter-institutional variations.
Moreover, in our patient population, low baseline myocardial uptake, defined as five-point scale
score of <3, showed a high capability in prediction of cardiac toxicity, with a positive predictive value
of 100%. In contrast, the opposite finding (high myocardial uptake, define as five-point scale score ≥3)
could not discriminate between high- and low-risk patients. As shown by our post hoc analysis,
in this subset of patients (high myocardial uptake) the cut-off value of LV-SUVmean = 2.015 is able to
distinguish between low (LV-SUVmean < 2.015, in which the percentage of cardiotoxic patients was
0%) and intermediate risk patients (LV-SUVmean < 2.015, in which the percentuage of cardiotoxic
patients was 31%). However, for the reasons explained above, this cut-off value, which is data-driven,
can be considered valid only in the present patient population, being theoretically dependent by
technical factors.
5. Limitations
This study presents some limitations. Firstly, due to the retrospective nature of the study, the size
of the study is limited to 36 patients. As a matter of fact, it depends by our strict population inclusion
criteria. However, these criteria allowed the identification of subjects in which the ABVD scheme was
administered with standard doses. On the other hand, due to the retrospective nature of the study,
a specific high-fat low-carbohydrate diet or pharmacologic preparation was not administered prior to
the FDG-PET/CT scan. Consequently, the analysis of DXR effect on myocardial FDG uptake might
have been hampered by the large variability of myocardial metabolic pattern under fasting conditions,
which is at least partially related to dietary regimen in the days before the scan. As a consequence,
our findings need to be confirmed by larger, multicentral, prospective studies.
6. Conclusions
The score-based approach to FDG-PET/CT images is a feasible method for predicting cardiac
toxicity in a population of young patients treated with DXR. With respect to SUV-based approach,
this method might, therefore, improve the inter-reader and inter-scanner variability, allowing the
evaluation of FDG-PET/CT images as a tool to predict DXR cardiotoxicity in a multicentral setting.
7. Compliance with Ethical Standards
All procedures performed in the present study were in accordance with the 1964 Helsinki
declaration and its later amendments or comparable ethical standards. The institutional review
board approved this study and all subjects signed a written informed consent related to the imaging
procedure, as part of our routine clinical care.
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